What is BioGenex Laboratories?
BioGenex S.R.L. is at the forefront of molecular pathology, specializing in the design, development, and commercialization of advanced, fully-automated systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The company's innovative eFISHency integrated workflow solution for FISH laboratories and its miRNA systems for characterizing cancer of unknown primary (CUP) and undifferentiated tumors are considered industry-disrupting technologies. BioGenex's automated molecular pathology workstations are recognized as the most advanced globally, complemented by a strong customer-focused approach that includes premier after-sales support and excellent technical service. This commitment to cutting-edge technology positions BioGenex years ahead of its competition in delivering sophisticated systems for both life science research and diagnostics.
How much funding has BioGenex Laboratories raised?
BioGenex Laboratories has raised a total of $649K across 2 funding rounds:
Debt
$350K
Debt
$299K
Debt (2020): $350K with participation from PPP
Debt (2021): $299K led by PPP
Key Investors in BioGenex Laboratories
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for BioGenex Laboratories?
The substantial enterprise-level capital infusion into BioGenex Laboratories signals a strategic move towards scaling its operations and expanding its market reach. With a recent major strategic investment, the company is poised to accelerate the development and deployment of its groundbreaking automated molecular pathology systems. This backing is likely to fuel further innovation, enhance manufacturing capabilities, and strengthen its global distribution network. The focus on advanced diagnostics and personalized medicine aligns with current healthcare trends, suggesting BioGenex is well-positioned for significant growth and market leadership in the coming years.
See full BioGenex Laboratories company page
